Vir Biotechnology Inc (VIR) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.

Total Revenue Chart for Vir Biotechnology Inc

Vir Biotechnology Inc (VIR) revenue for FY2025 was USD 68.6M, a -7.6% change from FY2024. Vir Biotechnology Inc's revenue grew from USD 2.7M in 2017 to USD 68.6M in 2025 (2431.6% over 8 years). Earnings per share moved from USD -10.02 in 2017 to USD 3.83 in 2022. Revenue compound annual growth rate: 5-year CAGR of -2.1%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$1.79B
Implied Share Price
$10.57
Enterprise Value
$282.48M
Revenue (TTM)
$303.23M
EBITDA
-$267.96M
Profit Margin
-83.00%
Trailing P/E
—
Forward P/E
4.27
Price/Book (MRQ)
0.83
Price/Sales (TTM)
5.90
EV/EBITDA
0.90
EV/Revenue
19.63
Dividend Yield
—
Book Value
$5.81
Free Cash Flow (FY2025)
-$396.61M
Free Cash Flow Yield
-22.17%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.